Prostate Cancer
Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer.
December 11, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
December 11, 2023
Dosimetric predictors for genitourinary toxicity in MR-guided stereotactic body radiation therapy (SBRT): Substructure with fraction-wise analysis.
December 8, 2023
The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort.
December 8, 2023
Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
December 8, 2023
Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy.
December 7, 2023
Association of PSMA PET-derived Parameters and Outcomes of Patients Treated for Oligorecurrent Prostate Cancer.
December 7, 2023
Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.
December 7, 2023
Activation of Dendritic Cells Isolated from the Blood of Patients with Prostate Cancer by Ex Vivo Fluid Shear Stress Stimulation.
December 6, 2023
Long-Term Impact of Medicaid Expansion on Prostate Cancer Screening.
December 6, 2023
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study.
December 6, 2023
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
December 6, 2023